Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor.

Kong PZ, Yang F, Li L, Li XQ, Feng YM.

PLoS One. 2013 Apr 19;8(4):e61591. doi: 10.1371/journal.pone.0061591. Print 2013.

2.

FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.

Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li XQ, Feng YM.

Cancer Lett. 2015 Oct 28;367(2):129-37. doi: 10.1016/j.canlet.2015.07.001. Epub 2015 Jul 22.

3.

FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.

Wang QS, Kong PZ, Li XQ, Yang F, Feng YM.

Breast Cancer Res. 2015 Feb 26;17:30. doi: 10.1186/s13058-015-0531-1.

4.

The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.

Lo PK, Lee JS, Liang X, Sukumar S.

Cell Signal. 2016 Oct;28(10):1502-19. doi: 10.1016/j.cellsig.2016.06.021. Epub 2016 Jul 1.

5.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

6.

Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.

Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Iwase H.

Clin Cancer Res. 2006 Nov 1;12(21):6410-4.

7.

CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.

Tunca B, Egeli U, Cecener G, Tezcan G, Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, Erturk E, Ak S, Cetintas S, Evrensel T.

Tumori. 2012 Mar-Apr;98(2):243-51. doi: 10.1700/1088.11937.

PMID:
22677992
8.

DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells.

Tian HP, Lun SM, Huang HJ, He R, Kong PZ, Wang QS, Li XQ, Feng YM.

J Biol Chem. 2015 Jul 31;290(31):19173-83. doi: 10.1074/jbc.M114.636126. Epub 2015 Jun 12.

9.

High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients.

Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, Sugiyama H, Noguchi S.

Clin Cancer Res. 2002 May;8(5):1167-71.

10.

Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.

Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K.

Clin Cancer Res. 2006 Feb 15;12(4):1201-7.

11.

Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.

Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.

Breast Cancer Res Treat. 2005 May;91(2):125-32.

PMID:
15868440
12.

FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients.

Kim MH, Koo JS, Lee S.

Oncology. 2013;85(2):128-36. doi: 10.1159/000351473. Epub 2013 Aug 13.

PMID:
23948758
13.

The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.

Salhab M, Reed MJ, Al Sarakbi W, Jiang WG, Mokbel K.

Breast Cancer Res Treat. 2006 Sep;99(2):155-62. Epub 2006 Mar 16.

PMID:
16541304
14.

[Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].

Zhang GH, Yang WT, Zhou XY, Zeng Y, Lu HF, Shi DR.

Zhonghua Yi Xue Za Zhi. 2007 Jan 16;87(3):155-60. Chinese.

PMID:
17425844
15.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
16.

Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.

Kim KJ, Huh SJ, Yang JH, Park W, Nam SJ, Kim JH, Lee JH, Kang SS, Lee JE, Kang MK, Park YJ, Nam HR.

Jpn J Clin Oncol. 2005 Mar;35(3):126-33.

PMID:
15741302
17.

The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.

Du X, Li XQ, Li L, Xu YY, Feng YM.

Breast Cancer Res Treat. 2013 Feb;138(1):59-67. doi: 10.1007/s10549-013-2432-2. Epub 2013 Feb 10.

PMID:
23397283
18.

Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Pliarchopoulou K, Kalogeras KT, Kronenwett R, Wirtz RM, Eleftheraki AG, Batistatou A, Bobos M, Soupos N, Polychronidou G, Gogas H, Samantas E, Christodoulou C, Makatsoris T, Pavlidis N, Pectasides D, Fountzilas G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):245-55. doi: 10.1007/s00280-012-2002-z. Epub 2012 Oct 25.

PMID:
23096218
19.

Transforming acidic coiled-coil-containing protein 2 (TACC2) in human breast cancer, expression pattern and clinical/prognostic relevance.

Cheng S, Douglas-Jones A, Yang X, Mansel RE, Jiang WG.

Cancer Genomics Proteomics. 2010 Mar-Apr;7(2):67-73.

PMID:
20335520
20.

ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.

Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H.

Clin Cancer Res. 2005 Jan 1;11(1):193-8.

Supplemental Content

Support Center